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ABSTRACT
Objective: The systematic development of an intervention to improve disease activity-based man-
agement of rheumatoid arthritis (RA) in daily clinical practice that is based on patient-level barriers. 
Methods: The self-management strategy was developed through a step-wise approach, in a pro-
cess of co-design with all stakeholders and by addressing patient level barriers to RA management 
based on disease activity. Results: The resulting DAS-pass strategy consists of decision supportive 
information and guidance by a specialised rheumatology nurse. It aims to increase patients’ knowl-
edge on DAS28, to empower patients to be involved in disease management, and to improve pa-
tients’ medication beliefs. The decision supportive information includes an informational leaflet and 
a patient held record. The nurse individualises the information, stimulates patients to communicate 
about disease activity, and offers the opportunity for questions or additional support. Conclusion: 
The DAS-pass strategy was found helpful by stakeholders. It can be used to improve RA daily clinical 
practice. Our systematic approach can be used to improve patient knowledge and self-management 
on other RA related topics. Also, it can be used to improve the management of other chronic con-
ditions. We therefore provide a detailed description of our methodology to assist those interested in 
developing an evidence-based strategy for educating and empowering patients.
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ORIGINAL PAPER
ABBREVIATIONS 
DAS: Disease Activity Score
DAS28: Disease Activity Score of 28 
joints
IPDAS: International Patient Decision 
Aids Standards
RA: Rheumatoid Arthritis
RCT: Randomized Controlled Trial
INTRODUCTION
International guidelines recommend 
rheumatologists to manage Rheumatoid 
Arthritis (RA) based on disease activity.1,2 
This implies that disease activity should 
be monitored regularly, and medication 
should be adapted accordingly.3 The 
preferred treatment strategies tight con-
Corresponding Author:  
Marieke J. Spijk-de Jonge, MSc
Radboud University Medical Centre, 
Radboud Institute for Health Sciences,  
IQ Healthcare, Nijmegen, The Netherlands
Radboud University Nijmegen Medical 
Centre
PO Box 9101 (114), 6500 HB Nijmegen, 
The Netherlands
Tel.: +31 24 3615305








trol and Treat-to-Target are based on this principle. DAS28 
is a validated and frequently used disease activity measure 
in RA. The DAS28 provides a value between 0 and 10, 
indicating level of disease activity. A DAS28 value equal 
to or below 3.2 indicates low disease activity and a value 
above 3.2 indicates moderate or high disease activity. 
Although tight control/Treat-to-Target has internationally 
become part of ‘good clinical practice’, there is room for 
improvement. Notwithstanding scientific publications, 
meetings, organizational changes and time-saving inter-
ventions to implement it in daily practice, RA manage-
ment based on disease activity is suboptimal.4-6 Despite 
the profound benefits for treatment outcomes with 
respect to patient functionality, pain and joint damage, 
patients are unaware of the importance of keeping dis-
ease activity low.7-13 Several studies show that patients 
are generally unaware of the long term consequences of 
high disease activity.5,14
Improving patient involvement in RA care could help 
to further improve RA management based on disease 
activity. Research shows that patients’ lack of knowl-
edge on (the importance of) disease activity, and their 
reservations towards changing medication regimen 
hinder RA management based on disease activity.5,14-19 
Patients do not always want to change their medication 
regimen when their rheumatologist thinks it is necessary: 
medication changes are highly associated with the con-
sequences of disease on their current health status (eg, 
pain, fatigue, and current functionality) as opposed to 
biomedical aspects of disease reflected by disease ac-
tivity and consequently progression of joint damage.15-18 
Moreover, patients’ fear of side effects and losing control 
over their disease makes them accept their current health 
state and prefer their current treatment.16,19 These patient 
preferences do not seem to be informed decisions, as 
patients lack knowledge about disease activity and its 
long-term consequences. In addition, patients with RA 
do wish to be more informed and involved.5,14,20-23
We systematically developed a self-management 
strategy to improve RA management based on disease 
activity in a process of co-design with all stakeholders 
and by addressing patient level barriers, focusing on 
patients’ knowledge and empowerment. In this article, 
we describe the development process of this strategy 
because this approach fits the current paradigm of 
shared decision making between physicians and pa-
tients. Care for chronic diseases is increasingly designed 
around the idea that patients should have a central role 
in their own care.24 There are several chronic diseases 
where patients’ expertise about their own lives can be 
utilised more to manage the great variation and hetero-
genic character of a disease.25 The DAS-pass strategy is 
an example of how generic, evidence-based information 
can be tailored for patients to develop an instrument 
that is feasible for use in daily clinical practice. Hence, 
we provide a detailed description of our methodology to 
assist those interested in improving patient education by 
developing an evidence-based strategy for empowering 
and educating patients with chronic diseases.
MATERIALS AND METHODS
A stepwise approach was taken to develop a pa-
tient-centred strategy tailored to patient-level barriers 
to disease activity-based management of RA, which is 
an important success factor for implementing evidence 
into daily clinical practice.26,27 Furthermore, the strategy 
was based on successful strategies from other chronic 
diseases and it was systematically developed in coop-
eration with stakeholders. The development process 
consisted of preliminary work, a content phase and a lay 
out phase (Figure 1).
Preliminary Work
The preliminary work in developing the strategy con-
sisted of defining patient-level barriers and of exploring 
the evidence and example materials on targeting the 
identified barriers. 
Step 1: Defining barriers
Within our research group, van Hulst et al. explored barriers 
to RA management based on disease activity by perform-
ing 28 semi-structured interviews (14 rheumatologists and 
14 patients) and 5 focus groups (2 with rheumatologists 
and 3 with RA patients).5,14 They found that several of the 
barriers exist on the level of the patient. According to both 
patients and rheumatologists, patients lack knowledge 
on the important role of disease activity in RA. Patients 
who do mention to be familiar with disease activity doubt 




the relevancy of the outcome, or do not realise that high 
disease activity levels influence long-term functionality and 
joint damage. Other studies underwrite the finding that 
patients do not always want to adapt medication in case 
of active disease.16,19 In addition, while rheumatologists 
are interested in objective measures of disease status and 
the progression of damage, patients are more interested 
in the subjective aspects of the disease like pain, fatigue, 
and current functionality.15,17-19
In summary, our barrier analysis led to three patient-level 
barriers: 1) most patients are unfamiliar with disease 
activity measures; 2) many patients are not equipped 
to be involved in treatment (decisions); and 3) patients 
generally prefer not to change their current medication 
regimen. Based on these barriers, our strategy aims 
to improve patients’ knowledge on (the importance of) 
disease activity, empower patients to be more involved in 
their treatment (decisions), and improve patients’ beliefs 
about medication (changes).
Step 2: Exploring evidence and example materials 
Based on previous research, we know that patient-cen-
tred strategies are effective in improving disease 
management.27-29 Decision aids and decision support 
interventions are designed to facilitate and improve 
patient-centredness. Randomised trials show that they 
stimulate patients to take a more central role in health-
care and improve patients’ knowledge about treatment 
options and expectations. They also appear to lead to 
treatment decisions that better fit patients’ preferences 
and to improved communication between patients and 
physicians.30,31 Furthermore, we know that patients need 
knowledge as well as empowerment to be able to play 
an important role in their own healthcare.32
From diabetes mellitus research, we learned that a 
patient-held record can improve treatment outcomes 
(HbA1c and diastolic blood pressure).28 Furthermore, the 
involvement of a nurse is effective in educating patients, 
facilitating adherence to treatment and the self-efficacy 
of the patients, while also embedding the improvement 
strategy in daily clinical practice.27,33,34
Based on this evidence, our self-management approach 
aims to include decision supportive information (including 
patient held records) and nurse-led strategies designed 
to improve patient-centredness.
Content phase
After the preliminary work, a coherent draft version of 
the content of the decision supportive information was 
developed as well as draft goals were formulated in a 
checklist to navigate nurses in leading the patient-cen-
tred strategy. During the content phase, the draft ma-
terials were improved through applying the International 
Patient Decision Aids Standards (IPDAS) criteria and in 
co-design with all stakeholders.
Step 3: Developing content while applying IPDAS criteria
The IPDAS collaboration has developed elaborate crite-
ria for rating the quality of existing patient decision aids 
and to help designing high quality decision aids.33 Our 
decision supportive information has many commonalities 
with decision aids. Both aim to increase patients’ knowl-
edge about (treatment of) their disease and to empower 
patients to communicate with their practitioners about it. 
Therefore many, though not all, of the IPDAS criteria were 
helpful in the development of the decision supportive 
information. The IPDAS criteria were used to improve the 
quality of the decision supportive information by check-
ing the comprehensiveness, presentation, and wording 
of the content.
Step 4: Adapting draft content
The draft content of the information was finalised by 
consulting an expert panel, two patient research partners, 
and eight rheumatology professionals several times. After 
each consultation, the draft content of the information was 
adapted. This cycle continued until there were only minimal 
remarks from the expert panel, patient research partners 
and professionals. This procedure is demonstrated by the 
cycle in the process map (Figure 1).
The expert panel consisted of MH (expert on imple-
mentation strategies), GE (expert on shared decision 
making), and LvH (expert on barriers to RA management 
based on disease activity). They were asked to review 
the content of the decision supportive information from 
their own expertise. Two patient research partners, ie, 
RA patients who are trained to cooperate in scientific 
research, collaborated in the development of the deci-
sion supportive information. They know the principles of 
performing research and are experts on representing the 
patient point of view in (the treatment of) their disease. 
With help of the patient research partners, content of the 
decision supportive information was adapted in several 
meetings. To make sure that the decision supportive 
information represented daily clinical practice, four rheu-
matologists (including PvR) and three specialized nurses 
from different hospitals cooperated in the development 
process. They were asked to provide feedback on the 
content of the decision supportive information.
Layout phase
After the layout of the decision supportive information 
and nurse checklist were developed, the layout of the 
strategy was developed. By consulting laymen, hospital 
information centres, and patients several times, it was 
ensured that the information was presented clearly, and 
was supportive of its content.
Step 5: Adapting draft layout
At the beginning of the layout phase, three laymen were 
consulted. The laymen had no expertise or connection 







to RA. They were asked to give feedback on layout 
and wording of the draft information in a meeting with 
the researchers. The draft was adapted after feedback 
of the laymen. Then, the layout of the draft information 
was finalized by consulting five patients and two hospital 
information centres several times. This procedure is 
demonstrated by the cycle in the process map (Figure 
1). After each consult, the draft layout of the information 
was adapted. This cycle continued until there were only 
minimal remarks from patients and hospital communica-
tions centres. 
Five randomly selected RA patients were asked to re-
view the draft. They were asked about their opinion on 
comprehensibility of information and on different layout 
options. The first time, the patients were consulted in a 
face-to-face meeting. Subsequently, they were consult-
ed via e-mail several times.
The patient communication departments of two different 
hospitals provided feedback on the layout of the decision 
supportive information, based on their experience in 
informing patients about their disease and its treatment.
RESULTS
Following a stepwise approach, we developed the 
DAS-pass self-management strategy based on identi-
fied barriers, on previous research, and in a process of 
co-design with all stakeholders. In summary, our barrier 
analysis led to three patient-level barriers that hinder the 
management of RA based on disease activity in daily 
clinical practice: Most patients are unfamiliar with disease 
activity measures, many patients are not equipped to be 
involved in treatment (decisions), and patients generally 
prefer not to change their current medication regimen. 
The DAS-pass strategy consists of two components 
aimed to lower these barriers. The first component, 
decision supportive information for patients, consists 
of an informational leaflet and a patient held record. 
The second component is guidance by a specialized 
rheumatology nurse. In Table 1, the full content of the 
DAS-pass strategy is mapped out. In this table, it can be 
seen that each subject is based on a strategy objective 
that is, in turn, based on a barrier.
Component I: Decision supportive information for 
patients
Informational leaflet: ‘What is my disease activity?’
The leaflet ‘What is my disease activity’ is designed to 
educate patients about disease activity and its impor-
tance for clinical outcomes. By providing RA patients 
with information on RA management based on disease 
activity, the informational leaflet aims to increase patients’ 
knowledge on the subject. Furthermore, it is designed to 
change patients’ medication beliefs by emphasizing the 
importance of a strict medication policy for good clinical 
outcomes (see appendix material for examples). In ad-
dition, patients are encouraged to ask for their disease 
activity and discuss their medication options with their 
rheumatologist or specialized rheumatology nurse. By 
encouraging patients to address their disease activity 
with their clinicians, the leaflet aims to empower patients 
to be able to manage their own treatment.32
Patient held record: ‘The DAS-passport’
The DAS-passport is a patient-held record, where pa-
tients can write down their own DAS28 score in a table 
and a graph to see changes in their disease activity over 
time, and information on their RA medication (changes) 
and on the topics they want to discuss with their pro-
fessional during the next consultation (see Appendix 
for examples). By adding an interactive component to 
the decision supportive information, patients should 
feel more involved and become better self-managers. 
In addition, the DAS-passport aims to increase the 
uptake of information. This should lead to an increased 
understanding of the concept of disease activity and the 
importance of keeping it low.27,35,36
Component II: Guidance by a specialised nurse
A specialised rheumatology nurse discusses the decision 
supportive information (component 1) during an individual 
consultation with each patient. A checklist was developed 
to navigate nurses in this consultation. The nurse aims to 
stimulate patients to communicate about their disease ac-
tivity during visits, to individualise the decision supportive 
information to the patients’ needs and to give the patients 
the opportunity to ask questions or ask for additional 
support. Guidance by a specialised rheumatology nurse is 
an important component of the patient-centred innovation 
strategy because it empowers patients to be more involved 
in their treatment in multiple ways. This component aims 
to optimise the uptake of information, activate patients, 
and improve their self-efficacy.34
DISCUSSION
The DAS-pass strategy is a self-management strategy 
that aims to improve RA care by focusing on patient-lev-
el barriers to optimal disease activity management. It 
was developed through a process of co-design with 
stakeholders and based on successful strategies from 
other chronic diseases. Until now, none of the innovation 
strategies on RA management based on disease activity 
focused on barriers at patient level, while we know that 
these barriers exist and that patient-centred strategies 
are effective in other disciplines.27-29 Despite efforts 
to implement management based on disease activity 
measures into RA daily practice, we learned that the 
lack of patient awareness about the principle hinders 
rheumatologists in adhering to it.14-19 Empowering and 
educating patients can improve communication between 
patients and physicians and enable patients to take the 
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initiative. In addition, when patients take initiative in moni-
toring their own disease activity using the DAS-passport, 
rheumatologists might be urged to follow the principle. 
Hence, the DAS-pass strategy should result in improved 
RA daily clinical practice and, ultimately, in patients expe-
riencing less functional problems and less joint damage.
The absence of patient-centred strategies does not 
mean that no previous efforts have been made to pro-
vide patients with education on disease management. 
With the growing attention for patient-centred care, 
patient education has become more important in RA 
management.1,2 However, with informational flyers alone, 
most patients do not have the proper tools. Patients 
need knowledge as well as empowerment to be able 
to play an important role in their own healthcare.32 The 
DAS-pass strategy addresses patients’ needs as it was 
based on patient-level barriers. Moreover, rheumatology 
nurses play an important role in the DAS-pass strategy 
CO-DESIGN OF A DISEASE ACTIVITY BASED SELF-MANAGEMENT APPROACH FOR PATIENTS WITH RHEUMATOID ARTHRITIS
Table 1. Content of the DAS-pass strategy.
Content Strategy element objectives Targeted barrier*
Informational leaflet 
Meaning of abbreviation ‘DAS28’ Increase knowledge 1
Variables in calculation of DAS28 Increase knowledge 1
Cut off values disease activity (low/moderate/high) Increase knowledge 1
Recommended frequency of DAS28 monitoring Increase knowledge
Empowerment
1, 2
Recommended cut-off points for medication intensification  Increase knowledge 1
Importance of medication adaptation for clinical outcomes Increase knowledge
Change medication beliefs
1, 3
Importance of patient communicating about DAS28 with 
rheumatologist and nurse
Empowerment 2
Role of rheumatologist in balancing medication and side effects 
and/or personal situation patients
Increase knowledge 1
Patients quotes about positive experiences with DAS28 Empowerment 2




General personal information Empowerment 2





DAS28 over time (graph) Empowerment
Change medication beliefs
2, 3
Questions to rheumatologist or nurse, per visit Empowerment 2
Guidance by specialized nurse 
Explain contents of leaflet, tailored to patients’ needs Increase knowledge
Empowerment
1, 2
Explain patient held record, tailored to patients’ needs Increase knowledge
Empowerment
1, 2
Fill in first data patient held record Empowerment 2
Stimulate asking questions Increase knowledge
Empowerment
1, 2
Stimulate use decision supportive information Empowerment 2
* 1: Patients are not aware of (the importance of) disease activity; 2: Patients are not involved in their treatment (decisions); 







because they tailor the strategy to patients’ individual 
needs and circumstances. Rheumatology nurses also 
play an important role in the embedding of the DAS-pass 
strategy in daily clinical practice. Typically, tasks of the 
rheumatology nurse include providing patient education 
and facilitating self-management.37 Providing them with 
carefully developed tools like the DAS-pass strategy can 
increase the effectiveness of nurses’ efforts and ensures 
the feasibility of the strategy in daily clinical practice. 
One of the ways to tailor the instrument to patients’ 
needs is to digitalise it. Modern healthcare approaches 
such as electronic patient portals provide us with the 
opportunity to make information even more accessible 
to patients. In our view, the DAS-pass materials lend 
themselves perfectly for such applications. We heard 
several patients indicating a preference for a digitalised 
tool, while others preferred the paper-based version. 
Moreover, the current, paper-based materials allow us to 
also reach patients who are not used to using digitalised 
information, to evaluate the effects of the strategy. In 
addition, we view the role of the rheumatology nurse, 
discussing the decision supportive information, as a 
crucial component of our strategy.
Even though the DAS-pass strategy was developed 
carefully, the strategy is not likely to fit the needs of every 
RA patient. Research shows that there are patient groups 
that are unwilling or incapable of playing an important 
role in their own disease management.21 We believe 
that there are patients for whom the DAS-passport is 
an unfit tool. However, patients’ needs do change over 
time. From the literature, we know that early RA patients 
generally have other needs than more ‘experienced’ RA 
patients.38,39 This asks for a certain awareness of health 
professionals regarding patient education. To make 
education a continuous and integral part of RA man-
agement, patients’ needs need to be assessed regularly 
and tools need to be available to fit changing needs. Our 
DAS-pass strategy has the ability to be tailored to meet 
those changing needs because of the important role of 
the specialised rheumatology nurse.
A possible limitation of our study is that the barrier 
analysis by van Hulst et al. dates from 2008-2010. It is 
possible that patient-level barriers have shifted since. 
Furthermore, van Hulst et al. limited their barrier study to 
the Netherlands.5,14,18 Therefore it cannot be confirmed 
that results are generalisable to other countries. However, 
more recent studies and studies from other countries 
than the Netherlands describe similar patient-level barri-
ers to optimal disease management in terms of treatment 
outcomes.15-17,19 Also, during our preliminary work, we 
used (among other materials) information materials on 
the Disease Activity Score by the National Rheumatoid 
Arthritis Society (United Kingdom), which indicates that 
RA patients in other European countries also need edu-
cation about disease activity.40 
We performed a Randomised Controlled Trial (RCT) to 
evaluate the effects of the DAS-pass strategy. In the 
Rheumatology department of a regional hospital in the 
Netherlands, 200 patients took part in the ‘What is my 
disease activity?’ trial. Of these patients, 100 received 
the DAS-pass strategy, whilst the other 100 patients 
received usual care. The RCT will show whether the 
DAS-pass strategy successfully empowers patients to 
be more involved in their treatment (decisions), improves 
their knowledge about disease activity in general and 
the DAS28 in particular, and improves their beliefs about 
(changing) medication. The preliminary outcomes of the 
strategy are positive. Rheumatologists and rheumatolo-
gy nurses report that they receive positive feedback from 
patients who received the strategy (Table 2). 
The DAS-pass strategy is a promising self-management 
approach to improving RA care as it was developed sys-
tematically: based on patient-level barriers, in a process 
of co-design with stakeholders, and based on successful 
strategies from other chronic diseases. By empowering 
and educating RA patients, the DAS-pass strategy aims 
to improve care through a patient-centred strategy: to 
improve communication about disease activity between 
patients and rheumatologists, and to enable patients to 
take the initiative in the management of their disease. The 
DAS-pass strategy was found helpful by stakeholders. 
This example shows how an evidence based, feasible 
and efficient strategy can be designed to improve patient 
knowledge about a chronic disease and involvement in 
its treatment. 
Our strategy can be used to improve RA daily clinical 
practice. Our systematic approach can be used to im-
prove patient knowledge and self-management on other 
RA related topics. Also, it can be used to improve the 
management of other chronic conditions. We therefore 
provide a detailed description of our methodology to as-
sist those interested in the development of an evidence 
based strategy for empowering and educating patients.
Table 2. Example of first responses to the DAS-pass 
strategy.
“Repeatedly patients brought their DAS-passport to a 
visit. They like to have insight into their disease activity 
and ask me questions about the DAS28” (rheumatologist)
“When disease activity gradually increases while tapering, 
a patient does not always feel it. Using the chart in the 
DAS-passport, I can explain why it might be necessary 
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Figure 1. Informational leaflet; Importance of medication adaptation for clinical outcomes.
Figure 2. Informational leaflet; Recommended cut-off points for medication adaptation.
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